Your browser doesn't support javascript.
loading
Exploring sulforaphane as neurotherapeutic: targeting Nrf2-Keap & Nf-Kb pathway crosstalk in ASD.
Shah, Ali; Varma, Manasi; Bhandari, Ranjana.
Afiliación
  • Shah A; Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, UGC- Centre of Advanced Study, Panjab University, 160 014, Chandigarh, India.
  • Varma M; Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, UGC- Centre of Advanced Study, Panjab University, 160 014, Chandigarh, India.
  • Bhandari R; Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, UGC- Centre of Advanced Study, Panjab University, 160 014, Chandigarh, India. rbhandari@pu.ac.in.
Metab Brain Dis ; 39(3): 373-385, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37249861
Autism spectrum disorders (ASD) are a family of complex neurodevelopmental disorders, characterized mainly through deficits in social behavior and communication. While the causes giving rise to autistic symptoms are numerous and varied, the treatment options and therapeutic avenues are still severely limited. Nevertheless, a number of signalling pathways have been implicated in the pathogenesis of the disease, and targeting these pathways might provide insight into potential treatments and future strategies. Importantly, alterations in inflammation, oxidative stress, and mitochondrial dysfunction have been noted in the brains of ASD patients, and among the pathways involved in these processes is the Nrf2 cascade. This particular pathway has been hypothesized to be involved in inducing both, inflammatory and anti-inflammatory/neuroprotective effects in the brain, sparking an interest in its use in ASD. Sulforaphane, a sulfur-containing phytochemical present mainly in cruciferous plants like broccoli and cabbage, has shown efficacy in activating the Nrf2 signaling pathway, which in turn brings about a protective effect on neuronal cells, especially against mitochondrial dysfunction. Its efficacy against ASD has not yet been evaluated, and in this paper, we attempt to discuss the therapeutic potential of this agent in the therapy of autism, with special emphasis on the role of the Nrf2 pathway in the disorder.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sulfóxidos / Isotiocianatos / Enfermedades Mitocondriales / Trastorno del Espectro Autista Límite: Humans Idioma: En Revista: Metab Brain Dis Asunto de la revista: CEREBRO / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sulfóxidos / Isotiocianatos / Enfermedades Mitocondriales / Trastorno del Espectro Autista Límite: Humans Idioma: En Revista: Metab Brain Dis Asunto de la revista: CEREBRO / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: India